Invesco Ltd. Acquires 31,617 Shares of GoodRx Holdings, Inc. $GDRX

Invesco Ltd. lifted its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 91.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 66,076 shares of the company’s stock after purchasing an additional 31,617 shares during the quarter. Invesco Ltd.’s holdings in GoodRx were worth $291,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Citizens Financial Group Inc. RI purchased a new position in GoodRx during the 1st quarter worth $44,000. Headlands Technologies LLC lifted its stake in GoodRx by 213.2% during the 1st quarter. Headlands Technologies LLC now owns 14,830 shares of the company’s stock worth $65,000 after acquiring an additional 10,095 shares in the last quarter. Total Wealth Planning & Management Inc. acquired a new position in GoodRx during the 4th quarter worth $68,000. Gotham Asset Management LLC lifted its holdings in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock valued at $82,000 after purchasing an additional 4,182 shares during the last quarter. Finally, SBI Securities Co. Ltd. grew its stake in shares of GoodRx by 13.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock valued at $100,000 after purchasing an additional 2,748 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GDRX has been the topic of a number of analyst reports. UBS Group lowered their target price on GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $6.00 target price on shares of GoodRx in a research report on Monday, August 11th. Finally, Raymond James Financial downgraded shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.80.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $4.00 on Monday. GoodRx Holdings, Inc. has a 12-month low of $3.31 and a 12-month high of $8.06. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The firm has a market cap of $1.39 billion, a PE ratio of 40.00, a PEG ratio of 1.74 and a beta of 1.23. The company’s 50 day moving average price is $4.51 and its two-hundred day moving average price is $4.45.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 EPS. Equities research analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.17% of the stock is owned by corporate insiders.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.